Probability of detecting a mutation dependent on the disease phase at the start of imatinib therapy.

Second-line patients are those patients who received interferon therapy before imatinib therapy. Patients were monitored using a direct sequencing technique at least every 6 months by the Adelaide group. Accelerated-phase patients (n = 52) had the highest probability compared to chronic-phase (CP) patients (second-line CP n = 91, de-novo CP n = 131).